| Title |
Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
|
|---|---|
| Published in |
Breast cancer targets and therapy, November 2012
|
| DOI | 10.2147/bctt.s37003 |
| Pubmed ID | |
| Authors |
Marcio Machado, Thomas R Einarson |
| Abstract |
To evaluate, from the perspective of the Brazilian public health care system, the cost-effectiveness of lapatinib plus capecitabine (LAP/CAP) versus capecitabine alone (CAP) or trastuzumab plus capecitabine (TRAST/CAP) in the treatment of women with human epidermal growth factor receptor-2-positive metastatic breast cancer previously treated with trastuzumab. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 66 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 21% |
| Student > Master | 8 | 12% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Doctoral Student | 4 | 6% |
| Student > Bachelor | 4 | 6% |
| Other | 11 | 16% |
| Unknown | 21 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 13% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Social Sciences | 4 | 6% |
| Economics, Econometrics and Finance | 3 | 4% |
| Other | 6 | 9% |
| Unknown | 24 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2012.
All research outputs
#17,408,360
of 25,540,105 outputs
Outputs from Breast cancer targets and therapy
#184
of 325 outputs
Outputs of similar age
#133,977
of 202,569 outputs
Outputs of similar age from Breast cancer targets and therapy
#4
of 6 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 325 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,569 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.